Table 2.

mTOR inhibitors in sensitization to chemotherapy

Condition	Rapalogs	Drug sensitized	Refs
Basic research
Breast cancer with AKT activation	RAD001	Letrozole and Fulvestrant	(Beeram et al., 2007)
Breast cancer with aberrant AKT activity	Rapamycin, CCI-799	Tamoxifen	(DeGraffenried et al., 2004)
Bronchial and peripheral murine lung carcinomas	Rapamycin	HKI-272 (a TKI)	(Li et al., 2007)
Squamous cell carcinoma of the head and neck	CCI-799	Erlotinib	(Jimeno et al., 2007)
PTEN-deficient and PTEN-intact glioblastoma cells	Rapamycin	Erlotinib	(Wang et al., 2006a)
Bcr/Abl-positive leukemia cells	Rapamycin, RAD001	Imatinib	(Dengler et al., 2005)
Bcr/Abl-transformed myeloid and lymphoid cells	Rapamycin	Imatinib	(Mohi et al., 2004)
Small cell lung cancer	Rapamycin	Imatinib	(Tsurutani et al., 2005)
Small cell lung cancer	CCI-799	Cisplatin	(Wu et al., 2005)
NSCLC	Rapamycin	Cisplatin	(Liu et al., 2007)
HER2/neu-overexpressing breast cancer cells	Rapamycin	Paclitaxel and carboplatin	(Mondesire et al., 2004)
B-cell neoplasm multiple myeloma (MM)	Rapamycin	Dexamethasone	(Stromberg et al., 2004)
PTEN-negative/Akt active prostate cancer	CCI-799	Doxorubicin	(Grunwald et al., 2002)
Preclinical study
PTEN loss ErbB2-overexpressing breast cancer	RAD001	Trastuzumab	(Lu et al., 2007)
Phase II study
Breast cancer	CCI-779 or RAD001	Letrozole	(Chollet et al., 2006)

TKI, EGFR tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer